Navigation Links
Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
Date:9/30/2009

ded our original expectation for enhancing ApoA-l production in humans," stated Donald J. McCaffrey, President and CEO of Resverlogix. "We know that the enhancement of ApoA-l and key RCT particles in the body is widely recognized by international experts as the necessary markers to potentially impact atherosclerosis regression. Hence, we have achieved another critically important clinical milestone for our Company," noted McCaffrey.

The Phase 1b/2a trial was a double blind safety and tolerance study which investigated the pharmacokinetics and also early pharmacodynamics effects of RVX-208. A total of 72 subjects enrolled in the trial. The study had three arms, a low dose arm with 24 subjects, a dose-escalation arm with 24 subjects, and a third high dose arm with 24 subjects. This trial also examined early markers for reverse cholesterol transport such as ApoA-l, HDL-c, pre-beta HDL and alpha HDL subparticles. Approximately half of the subjects had low levels of baseline HDL cholesterol.

Highlights from the study are as follows:

    -   The primary endpoint, plasma ApoA-I increase compared to placebo,
        achieved a range in all subjects of 5.1% - 10.4% in all doses at days
        8 and 28 respectively.
    -   At the lowest dose of 1mg/kg b.i.d. in subjects with low levels of
        HDL-c, plasma ApoA-l increases reached statistical significance of
        5.7% (p(less than)0.05) at day 8 and 7.8% (p(less than)0.05) at
        day 28.
    -   A critical RCT functionality marker, alpha-1 HDL particles,
        illustrated highly statistical significance with an increase of
        46.7% (p(less than)0.004), in all subjects and
        57.2% (p(less than)0.02) in the low dose arm over placebo at day 28.
    -   Pharmacokinetic parameters of RVX-208 were dose dependant with oral
        administration.
    -   RVX-208 was shown to be compatible with simvastatin (40mg).
    -   Seventy out of seventy two subjects completed the tria
'/>"/>
Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
2. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
3. Resverlogix Provides Quarterly Update
4. Resverlogix Board of Directors Update
5. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
6. Resverlogix Announces Closing of Debt Redemption
7. Resverlogix Eliminates Sixty Percent of Remaining Debt
8. Resverlogix Issues a Management Statement
9. Resverlogix Board of Directors Update
10. Resverlogix Notice of Conference Call & Webcast
11. Jan Gray Joins Resverlogix Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Freeslate, Inc ., the ... that Lupin Limited, one of India’s top five pharmaceutical ... PharmD System for high throughput solid form screening. ... on a wide range of quality, affordable generic and ...
(Date:1/14/2014)... 2014 Histogen, Inc., a regenerative medicine ... grown under simulated embryonic conditions, today announced that they ... Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary ... agreement is an amendment to the existing license between ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo announced ... from the National Institutes of Health (NIH) to help ... effective treatments to patients on a faster timeline. Organovo ... Sciences (NCATS) and the National Eye Institute (NEI) to ...
(Date:1/14/2014)... 14, 2014   Kinaxis ®, provider of RapidResponse ®, ... and operations planning ( S&OP ) service, is proud to ... which will be held at the Hilton San Diego Bayfront, ... customer Elisabeth Kaszas , Director of Supply Chain at ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... VIGILAIR Systems, an industry leader in Ultraviolet ... published, and first of its kind hospital study that ... (HAI) with the application of VIGILAIR® air cleaning technology ... The published article , Effect of enhanced ultraviolet germicidal ...
... BioNeutral Group, Inc. (OTCBB: BONU), a specialty life science ... J.D., as a new member to its Board of Directors. ... Wharton School of Business, University of Pennsylvania and received his ... been an attorney in the state of New Jersey since ...
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced ... its common stock pursuant to an effective shelf registration statement ... sole book-running manager in this offering and Sangamo will grant ... to 1,005,000 additional shares. The securities described ...
Cached Biology Technology:Newly Published Study Shows Dramatic Reduction in Hospital Acquired Infections 2BioNeutral Appoints Michael D. Francis, J.D. as Director to the Board 2BioNeutral Appoints Michael D. Francis, J.D. as Director to the Board 3Sangamo Announces Public Offering of Common Stock 2Sangamo Announces Public Offering of Common Stock 3
(Date:4/16/2014)... TALLAHASSEE, Fla. Florida State University researchers have identified ... deterioration of bone density and muscle mass with obesity. ... heavier you were the better your bones would be ... Ilich-Ernst, the Hazel Stiebeling Professor of Nutrition at Florida ...
(Date:4/16/2014)... Sometimes known as Kennedy,s disease, spinal and bulbar muscular atrophy ... progressive muscle weakness and atrophy. Researchers have long considered it ... the cells in the spinal cord and brainstem that control ... the April 16, 2014 online issue of Neuron , ...
(Date:4/16/2014)... , , Everything we do all of our movements, thoughts ... one another, and recent studies have suggested that some of ... known as astrocytes may be listening in on, or even ... study suggests that astrocytes might only be tuning in part ...
Breaking Biology News(10 mins):Researchers: Obesity can amplify bone and muscle loss 2Mutant protein in muscle linked to neuromuscular disorder 2Eavesdropping on brain cell chatter 2Eavesdropping on brain cell chatter 3
... BIO-key International, Inc.,(OTC Bulletin Board: BKYI), a leader ... that the U.S. Patent and Trademark,Office has approved the ... within a Biometric Security System" method. , ... protected by this patent (patent number,7,454,624) provide another layer ...
... Ore. December 3, 2008. The first 5-year forest inventory ... available to the public: California,s Forest Resources, 2001-2005: Five-Year ... findings from the report:, , Forests cover about ... acres is publicly managed. , Houses built in the ...
... Institution of Oceanography at UC San Diego returning ... details of vibrant sea life and ecosystems in ... species and marine animals previously never seen alive. ... depths, have revealed disturbing declines in sea-life populations ...
Cached Biology News:BIO-key(R) Granted Patent to Secure Biometric Enrollments From Unauthorized Use 2Forest inventories in California include more than trees 2Forest inventories in California include more than trees 3Expeditions reveal gulf of California's deep sea secrets, as well as human imprints 2Expeditions reveal gulf of California's deep sea secrets, as well as human imprints 3Expeditions reveal gulf of California's deep sea secrets, as well as human imprints 4
Mouse monoclonal antibody raised against a partial recombinant DHX8. NCBI Entrez Gene ID = DHX8...
... Mouse polyclonal antibody raised ... Immunogen: ... 241 a.a) partial recombinant protein ... Accession Number: NM_004693 ...
... DNA Visualizer DX's sensitivity of DNA detection has ... band in an agarose gel can be detected ... kit can be purified by organic solvent extraction ... commercially kits worked well.) DNA excised from ...
Mouse monoclonal antibody raised against a full length recombinant CSNK2A2. NCBI Entrez Gene ID = CSNK2A2...
Biology Products: